$792 Million is the total value of Avoro Capital Advisors LLC's 47 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
KITE | New | KITE PHARMA INC | $83,636,000 | – | 806,750 | +100.0% | 10.56% | – |
IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $30,512,000 | – | 4,151,343 | +100.0% | 3.85% | – |
NBIX | New | NEUROCRINE BIOSCIENCES INC | $10,097,000 | – | 219,500 | +100.0% | 1.28% | – |
SGMO | New | SANGAMO THERAPEUTICS INC | $7,040,000 | – | 800,000 | +100.0% | 0.89% | – |
ARGX | New | ARGENX SEsponsored adr | $4,573,000 | – | 215,597 | +100.0% | 0.58% | – |
NVRO | New | NEVRO CORP | $3,722,000 | – | 50,000 | +100.0% | 0.47% | – |
PTCT | New | PTC THERAPEUTICS | $2,200,000 | – | 120,000 | +100.0% | 0.28% | – |
New | SPDR S&P 500 ETFput | $1,456,000 | – | 250,000 | +100.0% | 0.18% | – | |
OVAS | New | OVASCIENCE INC | $489,000 | – | 313,316 | +100.0% | 0.06% | – |
MDCO | New | MEDICINES COcall | $50,000 | – | 200,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-06-14 |
13F-HR | 2024-05-15 |
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.